AT
NAVB

Arden Trust’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Arden Trust’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-914
Closed -$17K – 664
2016
Q1 		$17K Hold
914
– – ﹤0.01% 626
2015
Q4 		$24K Hold
914
– – ﹤0.01% 644
2015
Q3 		$42K Buy
+914
New +$34.5K ﹤0.01% 717

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Arden Trust's NAVB Position: Q2 2016 in Review

Arden Trust sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 914 shares — an estimated $17K sold.

Arden Trust first reported a position in NAVB in Q3 2015 and held it in 3 quarters. The position peaked at $42K in Q3 2015. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

  • Arden Trust reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • Arden Trust sold 914 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $17K.
  • Arden Trust first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2015 and held it in 3 quarters.
  • Arden Trust's Navidea Biopharmaceuticals Inc. position peaked at $42K in Q3 2015.
  • 63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Arden Trust's 13F filing for Q2 2016, filed 10 Aug 2016.